# Seres Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/seres-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.serestherapeutics.com/
- Total disclosed funding: $21M
- Latest round: Series B (May 23, 2014)
- Investors on record: 4

## About

Founded in 2010 and headquartered in Massachusetts, US, Seres Therapeutics, Inc. specializes in developing live biotherapeutics. In October 2025, Seres Therapeutics, Inc. received?USD 3.6 million in grant funding from CARB-X.

Seres Therapeutics is at the forefront of developing live biotherapeutics aimed at transforming patient health, particularly within medically vulnerable populations. Their core product offerings focus on innovative treatments designed to prevent bacterial bloodstream infections and combat antimicrobial resistance (AMR), alongside therapies for gastrointestinal (GI)-related immune diseases. These biotherapeutics leverage the company's proprietary microbiome restoration platform, which harnesses live microbes to restore balance to the gut microbiota. The company's products are targeted primarily at healthcare providers within hospitals and specialty clinics in North America and Europe, where there is a pressing need for effective treatments against resistant infections and GI disorders that significantly impact patients' quality of life.

The company generates revenue through strategic partnerships and collaborations with healthcare institutions and pharmaceutical companies, combining upfront payments, milestone payments tied to research and development success, and royalties on future product sales.

The organization plans to use the October 2025 funding to develop and manufacture a liquid formulation of SER-155 to improve accessibility for vulnerable patients who cannot take capsules.

## Funding rounds

- Series B, May 23, 2014, $11M — Flagship Pioneering, Alexandria Venture Investments, Mayo Clinic, Enso Ventures
- Series A, Nov 26, 2012, $4M — Flagship Pioneering
- Series A, Jun 1, 2012, $6.5M — Flagship Pioneering

## Investors

- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series A, Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- Mayo Clinic — Series B
- Enso Ventures (https://capitalatlas.ai/funds/enso-ventures) — Series B